New Paper Alert: Botensilimab and Balstilimab in Relapsed/Refractory Metastatic Sarcomas - OncoDaily Learn how a novel combination of Botensilimab and Balstilimab demonstrates promising efficacy in traditionally immunotherapy-resistant sarcomas.

New Paper Alert: Botensilimab and Balstilimab in Relapsed/Refractory Metastatic Sarcomas

oncodaily.com/oncolibrary/...

#10MostPromisingCancerDrugs #Agenus #Angiosarcoma #ASCO #Botensilimab #CancerCare #CancerResearch #Immunotherapy #Sarcoma #SarcomaResearch #Health #Medicine #NewPaperAlert